<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587194</url>
  </required_header>
  <id_info>
    <org_study_id>AP-CL-PSOR-PI-13156</org_study_id>
    <nct_id>NCT03587194</nct_id>
  </id_info>
  <brief_title>Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis</brief_title>
  <official_title>A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8,&#xD;
      non responders will be discontinued, partial responders will be given add-on Enstilar QD for&#xD;
      4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 adult patients with moderate to severe plaque psoriasis will be given OTEZLA® for 8 weeks.&#xD;
&#xD;
      At week 8, patients who achieved between PASI 25-74 response will receive 4 weeks of&#xD;
      Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% in addition to&#xD;
      continuing OTEZLA® therapy.&#xD;
&#xD;
      Patients who do not meet PASI 25 at week 8 will be discontinued from the study.&#xD;
&#xD;
      At week 12 (after 4 consecutive weeks of Enstilar® add on therapy), Enstilar® will be&#xD;
      discontinued and these patients will continue Otezla® as monotherapy through week 16.&#xD;
&#xD;
      Patients who achieve PASI 75 at week 8 will remain enrolled on Otezla® monotherapy through&#xD;
      week 16.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area Severity Index 75 at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients who achieve Psoriasis Area Severity Index 75 at week 12. PASI scores range 0-72 (maximal disease)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Otezla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Otezla BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Otezla</intervention_name>
    <description>Otezla 30mg BID</description>
    <arm_group_label>Otezla</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female adult ≥ 18 years of age;&#xD;
&#xD;
          2. Diagnosis of chronic plaque-type psoriasis&#xD;
&#xD;
          3. Moderate to severe plaque type psoriasis as defined at baseline by:&#xD;
&#xD;
               -  PGA score of 3 or greater&#xD;
&#xD;
               -  BSA affected by plaque-type psoriasis of 10% or greater&#xD;
&#xD;
               -  PASI ≥ 12&#xD;
&#xD;
          4. Able and willing to give written informed consent prior to performance of any&#xD;
             study-related procedures&#xD;
&#xD;
          5. Must be in general good health (except for disease under study) as judged by the&#xD;
             Investigator, based on medical history, physical examination, clinical laboratories,&#xD;
             and urinalysis. (NOTE: The definition of good health means a subject does not have&#xD;
             uncontrolled significant co-morbid conditions).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other than psoriasis, any clinically significant (as determined by the investigator)&#xD;
             cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal,&#xD;
             hematologic, immunologic disease, or other major disease that is uncontrolled.&#xD;
&#xD;
          2. Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or&#xD;
             guttate psoriasis) or drug induced psoriasis&#xD;
&#xD;
          3. Subjects who previously used any biologic agent for psoriasis.&#xD;
&#xD;
          4. Use of oral systemic medications for the treatment of psoriasis within 4 weeks&#xD;
             (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and&#xD;
             cyclosporine).&#xD;
&#xD;
          5. Patient used topical therapies to treat psoriasis on the hands and/or feet within 2&#xD;
             weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids,&#xD;
             vitamin D analogs, or retinoids).&#xD;
&#xD;
          6. Patient received UVB phototherapy within 2 weeks of Baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerry Bagel, MD</last_name>
    <phone>6094434500</phone>
    <email>dreamacres1@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elise Nelson</last_name>
    <phone>6094434500</phone>
    <email>enelson@windsordermatology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalyssa Delvalle</last_name>
      <phone>609-443-4500</phone>
      <phone_ext>1416</phone_ext>
      <email>jdelvalle@windsordermatology.com</email>
    </contact>
    <contact_backup>
      <last_name>Elise Nelson</last_name>
      <phone>6094434500</phone>
      <email>enelson@windsordermatology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jerry Bagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Keegan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Nieves, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

